Disease · MONDO_0015486

keratoconus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. keratoconus. Diseases, record MONDO_0015486. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015486

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: keratoconus; Open Targets
Open Targets ID: MONDO_0015486; Open Targets
Other names: keratoconus (disease); Open Targets
Disease Ontology: DOID:10126; Disease Ontology
MeSH: D007640; MeSH
NCI Thesaurus: C26806; NCI Thesaurus
Orphanet: ORPHA:156071; Orphanet
Orphanet: ORPHA:2335; Orphanet
Highest stage of its drugs: Approval, for 2 of its 16 drugs, from DailyMed and FDA; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIBOFLAVIN	CHEMBL1534	Small molecule	Approval	ClinicalTrials.gov, at phase 4	47	46	46	Drugs and targets
RIBOFLAVIN 5'-PHOSPHATE SODIUM	CHEMBL3989697	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
SODIUM IODIDE	CHEMBL1644695	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
INSULIN HUMAN	CHEMBL1201631	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PLATINUM	CHEMBL1235478	Small molecule	Phase 2	ClinicalTrials.gov	2	2	0	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
GLUTATHIONE	CHEMBL1543	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RETINOL	CHEMBL986	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	1	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 1/2	https://conductscience.org/library/genes/2908	Drugs and targets
PPIA	Peptidyl-prolyl cis-trans isomerase A	1	Cyclophilin A modulator	Unknown	https://conductscience.org/library/genes/5478	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	1	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme	Unknown	https://conductscience.org/library/genes/6616	Drugs and targets

Trials54

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01143389	Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia	Phase 2	510	2018-05-04	Keratoconus, Post-Refractive Ectasia	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT01398852	Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia	Phase 3	500	2013-03-04	Keratoconus and Ectasia	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT03442751	Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus	Phase 3	201	2024-01-30	Progressive Keratoconus	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT00647699	Corneal Collagen Cross-linking for Progressive Keratoconus	Phase 3	147	2016-07-07	Progressive Keratoconus	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT01190306	Safety Study of the VEGA UV-A System to Treat Keratoconus	Phase 3	127	2013-03-04	Keratoconus	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT01459679	Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery	Phase 3	1,721		Keratoconus, Corneal Ectasia	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT01081561	Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs	Phase 2/3	600		Keratoconus, Ectasia	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT04731727	Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)	Early phase 1	600		Keratoconus, Unstable	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT03922542	Comparison of Standard vs. Accelerated Corneal Crosslinking	Phase 2/3	508		Keratoconus, Ectasia Corneal	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT02095730	Corneal Cross-Linking Comparing Variables	Phase 3	500		Unstable Corneas	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 54

See all 54 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Riboflavin 0.1% Eyedrops Every 5 Minutes vs Riboflavin 0.1% Eyedrops Every 2 Minutes: deaths from any cause	0 of 253	0 of 257	510	NCT01143389	Trial comparisons
Riboflavin 0.1% Eyedrops Every 5 Minutes vs Riboflavin 0.1% Eyedrops Every 2 Minutes: serious adverse events	0 of 253	0 of 257	510	NCT01143389	Trial comparisons
Corneal Collagen Cross-linking (CXL) Treatment Group vs Control Group: serious adverse events	0 of 73	3 of 74	147	NCT00647699	Trial comparisons
CXL Treatment vs Sham Control: serious adverse events	0 of 61	0 of 66	127	NCT01190306	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20164744	RESULT	1	PubMed
20138607	RESULT	1	PubMed
18811118	RESULT	1	PubMed
18471635	RESULT	1	PubMed
17720054	RESULT	1	PubMed
17531694	RESULT	1	PubMed
17457184	RESULT	1	PubMed
17457183	RESULT	1	PubMed
16952090	RESULT	2	PubMed
16900027	RESULT	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015486

GET https://conductscience.org/api/diseases/v1/MONDO_0015486/trials?page=2

API reference For AI assistants